Serious Adverse Events – Page 12 – Communicable Diseases Research

Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials

성인에서 COVID-19에 대한 재조합 직렬 반복 이량체 RBD 기반 단백질 서브유닛 백신(ZF2001)의 안전성 및 면역원성: 2건의 무작위 배정, 이중 맹검, 위약 대조, 1상 및 2상 시험

Clinical Trial

Published on 2021-08-012022-09-12
Journal: The Lancet. Infectious Diseases [Category] MERS, SARS, 임상, 진단,

Impact of an interactive web tool on patients’ intention to receive COVID-19 vaccination: a before-and-after impact study among patients with chronic conditions in France

Research

Published on 2021-07-312022-10-27
Journal: BMC Medical Informatics and Decision Making [Category] COVID-19,

Impact of an interactive web tool on patients’ intention to receive COVID-19 vaccination: a before-and-after impact study among patients with chronic conditions in France

Research

Published on 2021-07-312022-10-27
Journal: BMC Medical Informatics and Decision Making [Category] Coronavirus, COVID-19, SARS,

Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia

코로나19 폐렴으로 입원한 환자의 토파시티닙

Randomized Controlled Trial

Published on 2021-07-292022-09-11
Journal: The New England Journal of Medicine [Category] Fulltext, MERS, 임상, 치료제,

[키워드] 1:1 95% CI 95% confidence interval adverse event all-cause mortality assigned Brazil coronavirus disease Coronavirus disease 2019 COVID-19 pneumonia cumulative cumulative incidence death dose Efficacy and safety glucocorticoid Glucocorticoids hazard ratio hospital discharge Hospitalization Hospitalized incidence inhibitor Janus kinase Kinase inhibitor lower risk Mortality occurred Occurrence Ordinal Scale Patient patients hospitalized Pfizer Placebo placebo group Pneumonia Primary outcome randomization Randomly receive Respiratory failure risk risk ratio Serious Adverse Events STOP-COVID the patient the placebo group Tofacitinib
[DOI] 10.1056/NEJMoa2101643 PMC 바로가기 [Article Type] Randomized Controlled Trial

Phase I/II Clinical Trial of Autologous Activated Platelet-Rich Plasma (aaPRP) in the Treatment of Severe Coronavirus Disease 2019 (COVID-19) Patients

Research Article

Published on 2021-07-072022-10-29
Journal: International Journal of Inflammation [Category] COVID-19,

[키워드] activated administration analyzed anti-inflammatory cytokine C-reactive protein cause clinical COVID-19 CRP CRS Cytokine release syndrome Cytokine storm demonstrated disease duration of hospitalization Efficacy Enrollment evaluate growth factor heart failure ICU increase in intensive care LCR lymphocyte median Mortality neutrophil Neutrophils nine NLR outbreak outcome oxygen Patient phase platelet-rich plasma Proinflammatory cytokine Public Regional Result Safe secondary secondary outcome Serious Adverse Events severe COVID-19 patient severe COVID-19 patients significantly suppress therapy transferred treat Trial
[DOI] 10.1155/2021/5531873 PMC 바로가기 [Article Type] Research Article

Efficacy and safety of remdesivir in COVID-19 caused by SARS-CoV-2: a systematic review and meta-analysis

SARS-CoV-2로 인한 COVID-19에서 렘데시비르의 효능 및 안전성: 체계적인 검토 및 메타 분석

Meta-Analysis

Published on 2021-06-242022-09-11
Journal: BMJ Open [Category] SARS, 치료제,

[키워드] 95% CI Analysis applied article benefit caused Clinical improvement clinical pharmacology Cochrane Central Cochrane review control group controlled trials COVID-19 decrease Effectiveness Efficacy eligibility eligible Evidence faster immunology Meta-analysis Methodological quality moderate Mortality no difference outcome participant patients Perspective Primary outcome randomised controlled trial RCT RCTs registration number Remdesivir Respiratory failure respiratory infections risk risk of bia RNA polymerase inhibitor screened secondary outcome Secondary outcomes Serious Adverse Event Serious Adverse Events shown Significant significant decrease Standard of care systematic review Treatment treatment of COVID-19 was done was performed was used with COVID-19
[DOI] 10.1136/bmjopen-2020-048416 PMC 바로가기 [Article Type] Meta-Analysis

Assessing the efficacy and safety of hydroxychloroquine as outpatient treatment of COVID-19: a randomized controlled trial

COVID-19의 외래 환자 치료로서 하이드록시클로로퀸의 효능 및 안전성 평가: 무작위 대조 시험

Randomized Controlled Trial

Published on 2021-06-182022-09-11
Journal: CMAJ open [Category] SARS, 임상, 치료제,

[키워드] 95% confidence interval Assessing assigned Chain Reaction Community Composite conducted Contact contact with Controlled trial COVID-19 COVID-19 pandemic death determine determined by did not reduce direct contact disposition effect of treatment Efficacy and safety eligible enrolment Evidence expected First wave Follow-up hazard ratio Hospitalization hospitalizations hospitalized patient hospitalized patients Hydroxychloroquine hydroxychloroquine group hydroxychloroquine treatment identification individual Invasive mechanical ventilation matching placebo mechanical ventilation Mortality outcome outcomes Outpatient outpatients participant Participants patients PCR test Placebo placebo group polymerase chain polymerase chain reaction positive RT-PCR Prevent prevented Primary outcome priority raised Randomized controlled trial Randomly reduced resulting reverse transcription reverse transcription polymerase chain reaction Ribonucleic acid RT-PCR Safety SARS-COV-2 infection secondary Secondary outcomes Serious Adverse Event Serious Adverse Events severe COVID-19 study drug survived symptom duration symptom onset the placebo group therapy Treatment Trial viral ribonucleic acid with COVID-19
[DOI] 10.9778/cmajo.20210069 PMC 바로가기 [Article Type] Randomized Controlled Trial

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial

HIV 감염에서 SARS-COV-2에 대한 Chadox1 NCOV-19 (AZD1222) 백신의 안전성 및 면역 원성 : 2/3 상 임상 시험의 단일 암 보체.

Clinical Trial

Published on 2021-06-182022-08-13
Journal: The Lancet. HIV [Category] MERS, SARS, 임상, 진단,

[키워드] ACHE age All participants analysed analyses anti-Spike IgG anti-spike IgG response Anti-spike IgG responses antibody Antiretroviral therapy ART AstraZeneca available data AZD1222 CD4 CD4 cell CD4 count CD4 counts Cell cell-mediated immune response Cell-mediated immune responses cellular response Cellular responses ChAdOx1 ChAdOx1 nCoV-19 chill chills Clinical research clinical trial Coalition Comorbidity determined by dose Eligible participants ELISA ELISPOT enrolled enrolment enzyme enzyme-linked immunospot assay fatigue finding FIVE frequencies Frequency functional funding General population headache HIV HIV clinics HIV-negative HIV-uninfected humoral Humoral response humoral responses IFN-γ IgG response IgG responses immune responses Immunity immunogenic immunogenicity injection injection site Innovation IQR joint joint pain less Live virus Local London magnitude malaise male median median age muscle ache nausea network neutralisation NIHR NIHR Oxford Biomedical Research Centre no correlation no difference occurred Open-label outcome Oxford Pain participant Participants peaked people with HIV persistence phase 2/3 phase 2/3 trial plasma Primary outcome Primary outcomes prime-boost regimen proliferation proliferative protocol reactogenicity Registered reported required response Safe Safety SARS-CoV-2 SARS-CoV-2 spike-specific Serious Adverse Event Serious Adverse Events single-arm South sustained systemic reaction systemic reactions T-cell the vaccine undetectable vaccination Vaccine vaccine immunogenicity Valley Viral Viral load were measured with HIV
[DOI] 10.1016/S2352-3018(21)00103-X PMC 바로가기 [Article Type] Clinical Trial

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

60세 이상의 건강한 성인을 대상으로 한 불활성화 SARS-CoV-2 백신(CoronaVac)의 안전성, 내약성 및 면역원성: 무작위, 이중 맹검, 위약 대조, 1/2상 임상 시험

Randomized Controlled Trial

Published on 2021-06-012022-09-11
Journal: The Lancet. Infectious Diseases [Category] MERS, SARS, 임상, 진단, 치료기술,

[키워드] Adults Adverse reaction Adverse reactions age All participants Aluminium aluminium hydroxide antibody Antibody Response Antibody titre assigned baseline Beijing block Block randomisation China Chinese clinical trial CoronaVac COVID-19 COVID-19 vaccine Cutoff defined detectable development dose dose-escalation double-blind eight Endpoint enrolled groups healthy hydroxide immunogenicity inactivated injection injection site pain intervention group Intramuscular injection investigators Laboratory live SARS-CoV-2 Mild moderate morbidity morbidity and mortality Neutralising Antibodies neutralising antibody neutralising antibody titres occurred Older Older adults participant Participants Phase 1 Phase 2 phase 3 trial Placebo placebo group placebo-controlled positive primary immunogenicity Program random assignment randomised Randomly receive Registered reported research and development Safe Safety safety population SARS-CoV-2 SARS-CoV-2 vaccine Science second dose Serious Adverse Events Seroconversion seroconversion rate seronegative seropositive Seven severity technology the disease the placebo group titre Tolerability treatment allocation trial protocol vaccination Vaccine virus
[DOI] 10.1016/S1473-3099(20)30987-7 PMC 바로가기 [Article Type] Randomized Controlled Trial

Vitamin D supplementation for the treatment of COVID-19: a living systematic review

COVID-19 치료를 위한 비타민 D 보충: 살아있는 체계적인 검토

Article

Published on 2021-05-242022-09-11
Journal: The Cochrane database of systematic reviews [Category] 임상,

[키워드] 95% CI 95% confidence interval acute respiratory syndrome addressed Administered adverse event adverse events age all-cause mortality approach Arm Asymptomatic Asymptomatic disease baseline benefit Blood level blood levels calcifediol certainty certainty of evidence cholecalciferol clinical clinical status Cochrane COVID-19 Study Register comparability Consistency control group control groups coronavirus disease coronavirus diseases COVID-19 COVID-19 symptoms daily dose Data collection death decrease described determine died disease disease severity dose effective Effectiveness Effects Ethnicity event Evidence excluded Gender Health Organization heterogeneity High dose higher risk hospital discharge hypercalcaemia identify include indicate individual individuals inflammatory markers information Invasive mechanical ventilation investigated life maintain MERS methodological methodology Middle East Middle East respiratory syndrome Mild Mild disease moderate moderate or severe disease moderate to severe Mortality multiple dose multiple doses nine oral calcifediol oral cholecalciferol outcome outcomes participant Participants people with COVID-19 Placebo placebo group placebo treatment Population progression Quality Quality of life randomisation randomised controlled trial Randomised controlled trials RCT RCTs recording reported required risk of bia risk ratio Safe Safety searched Selection selective Serious Adverse Event Serious Adverse Events Severe acute respiratory syndrome severe disease Standard of care subject syndrome systematic review the placebo group the WHO treated Treatment treatment for COVID-19 treatment of COVID-19 viral clearance Vitamin D vitamin D serum Vitamin D status Vitamin D supplementation vomiting Web of Science WHO World Health Organization
[DOI] 10.1002/14651858.CD015043 PMC 바로가기 [Article Type] Article